Novavax, Inc. NVAX
10.20 USD -0.69 (-6.34%)
At closeNov 10, 2026, 7:56 PM EST
10.14 -0.06 -0.59%
After hours · Nov 10, 7:56 PM ET
10.07 Day range 10.71
6.20 52-week range 13.39
- YTD
- +51.79%
- 1 year
- +43.46%
News
zacks.com Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
zacks.com NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
benzinga.com B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.
marketbeat.com Novavax Q3 Earnings Call Highlights Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone…
seekingalpha.com Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
zacks.com Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
benzinga.com Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $235.000 million-$275.000 million to $385.000 million-$415.000 million vs $380.285 million estimate.
prnewswire.com Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D…
zacks.com Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's…
prnewswire.com Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs…
prnewswire.com Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S.…
247wallst.com Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big…
zacks.com Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.
zacks.com Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
defenseworld.net Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened Novavax, Inc. (NASDAQ: NVAX - Get Free Report) shares traded down 9.1% during trading on Friday. The stock traded as low as $11.57 and last traded at $11.6480. Approximately 2,002,169 shares traded…
reuters.com Novavax shareholder Shah Capital to step back from activist role Novavax shareholder Shah Capital to step back from activist role
barrons.com Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
247wallst.com Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide…
benzinga.com Citigroup Maintains Sell on Novavax, Raises Price Target to $8 Citigroup analyst Geoff Meacham maintains Novavax (NASDAQ:NVAX) with a Sell and raises the price target from $7 to $8.
zacks.com Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.
zacks.com Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
247wallst.com Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands…
benzinga.com Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
benzinga.com Transcript: Novavax Q2 2026 Earnings Conference Call Novavax (NASDAQ:NVAX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…
benzinga.com Novavax Stock Falls Back: What's Going On? Novavax is pulling back Tuesday after surging more than 20% Monday. Vaccine stocks rallied on a suspected pneumonic plague case in Russia.
benzinga.com Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose…
benzinga.com Novavax, Nvidia, MercadoLibre, Nu Holdings and PTC: Why These 5 Stocks Are on Investors' Radars Today NVAX, NVDA, MELI, NU, PTC were among the stocks seen trending on Monday, Oct. 5, 2026.
benzinga.com Novavax Shorts on Edge as Russia Plague Fears Spread Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.
benzinga.com What's Going On With Novavax Stock? Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot…
benzinga.com Novavax Stock Climbs Monday: What's Going On? Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine approvals and broader biotech strength.
benzinga.com Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc.…
benzinga.com Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant Novavax, Inc.'s (NASDAQ:NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the…
benzinga.com QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
benzinga.com Novavax Stock Rallies Tuesday: What's Happening? Shares of Novavax are trading higher Tuesday morning as buying interest continues across late-stage vaccine developers.
benzinga.com Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
benzinga.com Novavax Stock Moves Higher Wednesday: What's Driving the Action? Shares of Novavax Inc (NASDAQ: NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers.
benzinga.com Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children https://youtu.be/H_RititNE8U- benzinga.com Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $230.000 million-$270.000 million to $235.000 million-$275.000 million vs $389.234 million estimate.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby, CoreWeave, Salesforce, Lucid and more.
benzinga.com Novavax Stock Is Surging Monday: What's Driving The Action? Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
benzinga.com AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto…